Biomarin Pharmaceutical (BMRN) Current Deferred Revenue (2009 - 2017)
Biomarin Pharmaceutical's (BMRN) quarterly Current Deferred Revenue came in at $17.4 million in Q3 2017, up 1669.54% on a QoQ basis from $985000.0 in Q4 2016.
Powered by 
Analysis
Biomarin Pharmaceutical (BMRN) Current Deferred Revenue (2009 - 2017) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 5 years of Current Deferred Revenue data on file, last reported at $17.4 million in Q3 2017.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $17.4 million in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $17.4 million (changed N/A YoY) and the FY2016 annual result came in at $985000.0, changed N/A from the prior year.
- Current Deferred Revenue rose to $17.4 million in Q3 2017, from $985000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $17.4 million in Q3 2017 to a low of $985000.0 in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2017 | 17.43 Mn |
| Dec 31, 2016 | 985,000.00 |
| Sep 30, 2012 | 1.08 Mn |
| Jun 30, 2012 | 1.11 Mn |
| Dec 31, 2011 | 342,000.00 |
| Dec 31, 2009 | 86,000.00 |